An observational study in Carpal Tunnel Syndrome and Median Neuropathy, Carpal Tunnel, sponsored by Ahram Canadian University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-10.
Sponsored by Ahram Canadian University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 7 observational ones, and was the 1st registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:
Ahram Canadian University · Sites in Egypt
Ages 18–60 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–45 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–60
Ahram Canadian University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 10 started in 2023.
This study's planned enrollment of 50 is below the median of 92 across 131 observational studies indexed under Carpal Tunnel Syndrome.
Median enrollment 92 across the 3 interventional studies, 50 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.
The study population will be recruited from a single center and will include at least 50 individuals with CTS. The population may include individuals of all ages, but the study will likely focus on middle-aged and older adults, as CTS is more common in this population.
The study population will be diverse in terms of gender and race/ethnicity to ensure that the study findings are generalizable to a broader population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study will follow a group of individuals with carpal tunnel syndrome (CTS) according to Bland's grading scale (grades 1-3) to assess the role of inflammation in CTS. Participants will undergo clinical and biochemical evaluations to assess inflammatory markers and CTS severity. The study will follow participants over time to determine the relationship between inflammation and CTS, which can inform the choice of transdermal drug administration.
Diagnostic Test: Inflammatory markers
Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
The relationship between inflammatory markers and symptom severity of carpal tunnel syndrome (CTS).
interleukin-6, tumor necrosis factor-alpha using blood tests. Symptom severity will be assessed with standardized questionnaire "the Boston Carpal Tunnel Questionnaire".
Time frame: Changes of inflammatory markers and symptoms severity at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline
The relationship between inflammatory markers and grip strength of patients with CTS.
interleukin-6, tumor necrosis factor-alpha using blood tests. functional status by grip strength using a dynamometer.
Time frame: Changes of inflammatory markers and grip strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline
The relationship between inflammatory markers and pinch strength of CTS patients.
interleukin-6, tumor necrosis factor-alpha using blood tests. pinch strength will be measured using a dynamometer
Time frame: Changes of inflammatory markers and pinch strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline
The relationship between inflammatory markers and nerve conduction study of patients with CTS
interleukin-6, tumor necrosis factor-alpha using blood tests. Nerve conduction study results (motor and sensory distal latency of median nerve and amplitude) will be used to determine CTS severity based on Bland's grading scale.
Time frame: Changes of inflammatory markers and nerve conduction study at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline
Plan to share: Yes — The individual participant data (IPD) collected during this study will be available upon reasonable request. Requests for access to the data should be submitted via email to mohamed.elmeligie@acu.edu.eg. All requests will be reviewed by the study investigators to ensure that they are reasonable and consistent with the ethical principles of the study. Access to the data will be granted in compliance with applicable laws and regulations, and with appropriate safeguards to protect the privacy and confidentiality of study participants.
Supporting information: Statistical analysis plan, Informed consent form
Time frame: After finishing the trial and up to 1 year.
Access criteria: via email to mohamed.elmeligie@acu.edu.eg
No publications or documents are linked to this record.
Start is estimated for May 2023; primary completion for Sep 2023, 3 months later.
Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 3 months is below that.
Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahram Canadian University